logo

Latin America Liver Cancer Treatment Market Size (2024 - 2029)

The Latin American liver cancer treatment market is anticipated to experience significant growth, driven by an increase in risk factors associated with the disease. Lifestyle changes have led to a higher exposure to these risk factors, which include hepatitis, type-2 diabetes, metabolic disorders, obesity, alcohol consumption, and tobacco smoking. The rising prevalence of obesity, particularly in Latin American countries, further contributes to the expansion of the market. As these factors continue to influence the population, the market size is expected to grow in the coming years.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Oncology Drugs Research Latin America Liver Cancer Treatment Market Market Size

Market Size of Latin America Liver Cancer Treatment Industry

latin america liver Picture 1
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 7.90 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Latin America Liver Cancer Treatment Market Analysis

The Latin American liver cancer treatment market is expected to register a CAGR of nearly 7.9% during the forecast period. Changes in the current lifestyle of individuals led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type-2 diabetes, metabolic disorders, excess body weight, alcohol consumption, and tobacco smoking. It has also been observed that liver cancer risk increases substantially with the increase in one's body mass index (BMI). According to the OECD Obesity Update 2017, obesity levels are particularly high in Latin American countries. For example, in Mexico, 32.4% of males aged 15 years and over are obese as of 2017, and nearly 39% of the population is projected to become obese by 2030. Thus, owing to the above factors, the market is expected to show growth in the near future.

Latin America Liver Cancer Treatment Industry Segmentation

As per the scope of the report, liver cancer is a cancer that begins in the cells of the liver. The most common type of liver cancer is hepatocellular carcinoma, which begins in the liver cell called (hepatocyte). Other types of liver cancer, such as intrahepatic cholangiocarcinoma and hepatoblastoma, are much less common. The Latin American liver cancer treatment market is segmented by type, therapy, and geography.

By Type
Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types
By Therapy
Targeted Therapy
Radiation Therapy
Immunotherapy
Chemotherapy
Other Therapies
Geography
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Need A Different Region Or Segment?
Customize Now

Latin America Liver Cancer Treatment Market Size Summary

The Latin American liver cancer treatment market is poised for significant growth, driven by lifestyle changes that have increased exposure to risk factors such as hepatitis infections, type-2 diabetes, obesity, and alcohol and tobacco use. These factors have contributed to a higher incidence of liver cancer, particularly hepatocellular carcinoma, which is prevalent in individuals with chronic liver diseases like cirrhosis. The region's obesity rates, notably high in countries like Mexico, further exacerbate the risk, leading to a rising demand for liver cancer therapeutics. The market's expansion is fueled by the increasing incidence of liver cancer and the substantial unmet medical needs in the region.

The market landscape is characterized by a consolidation of major players, particularly in the diagnostics sector, where high-cost imaging modalities like MRI, CT, and PET scanners are essential. Despite the limited demand in Latin America, a few global companies dominate the market, while several niche players and ongoing clinical trials contribute to the therapeutic space. Key companies such as Bayer AG, Bristol-Myers Squibb Company, Merck & Co., Inc, and others are pivotal in shaping the market dynamics. The disparity in incidence rates between developed and developing countries in the region highlights the critical need for effective liver cancer treatments and diagnostics.

Explore More

Latin America Liver Cancer Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Burden of Liver Cancer

      2. 1.2.2 Technological Advancements in Treatments by Biopharmaceutical Companies

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Effects of Drugs

      2. 1.3.2 High Cost

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Type

      1. 2.1.1 Hepatocellular Carcinoma

      2. 2.1.2 Cholangio Carcinoma

      3. 2.1.3 Hepatoblastoma

      4. 2.1.4 Other Types

    2. 2.2 By Therapy

      1. 2.2.1 Targeted Therapy

      2. 2.2.2 Radiation Therapy

      3. 2.2.3 Immunotherapy

      4. 2.2.4 Chemotherapy

      5. 2.2.5 Other Therapies

    3. 2.3 Geography

      1. 2.3.1 Latin America

        1. 2.3.1.1 Mexico

        2. 2.3.1.2 Brazil

        3. 2.3.1.3 Argentina

        4. 2.3.1.4 Rest of Latin America

Latin America Liver Cancer Treatment Market Size FAQs

The Latin America Liver Cancer Treatment Market is projected to register a CAGR of 7.90% during the forecast period (2024-2029)

Bayer AG, Bristol-Myers Squibb Company, Merck & Co., Inc, Eisai Inc. and Exelixis, Inc are the major companies operating in the Latin America Liver Cancer Treatment Market.

Latin America Liver Cancer Treatment Report Snapshots

Latin America Liver Cancer Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)